

Product Datasheet


PF-07853578

Catalog No. **BP-00756** · CAS **3036158-98-9** · Form **free base** · Physical state **solid** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target PNPLA3	Research area Metabolic Disease; Cancer
-------------------------	---

Molecular formula	C₁₆H₁₉ClF₂N₂O₄S
Molecular weight	408.8480



DESCRIPTION

PF-07853578 (Example 11) is a PNPLA3 degrader with an EC₅₀ of 8 nM. PNPLA3 degrader-1 can be used in the study of cirrhosis and hepatocellular carcinoma.

BIOLOGICAL ACTIVITY

In Vitro

PF-07853578 (Example 11) exhibits EC₅₀ values of 5 nM (lipid droplet localization assay) and 8 nM (Western blot assay) against hPNPLA3-I148M in human hepatocytes.

In Vivo

PF-07853578 (30 mg/kg; diet administration; 14 days) reduces PNPLA3 protein levels and decreases hepatic triglyceride accumulation in BAC-TG transgenic mice fed a high-sucrose diet.

SOLUBILITY

Soluble in DMSO

In vitro DMSO : 100 mg/mL

REFERENCES

- [1]. Justin Dran BOYD, et al. Use of patatin-like phospholipase domain-containing protein 3 compounds. WO2024084363A1. 2024-04-25.
- [2]. Lindén D, et al. Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis. Liver Int. 2025;45(4):e16186.